

Relation of Gut Lactobacillus Acidophilus and Atherosclerosis in type 2 diabetic patients with and without atherosclerosis

A Thesis

*Submitted for Partial Fulfillment of M.D. degree
in Internal Medicine*

Presented By

Mark Nabil Bios

Master degree in Internal Medicine

Under Supervision of

Dr. Salwa Seddik Hosny

*Professor of Internal Medicine & Endocrinology
Faculty of Medicine Ain-Shams University*

Dr. Rania Sayed Abd El Baky

*Professor of Internal Medicine & Endocrinology
Faculty of Medicine Ain-Shams University*

Dr. Yara Mohamed Eid

*Professor of Internal Medicine & Endocrinology
Faculty of Medicine Ain-Shams University*

Dr. Nagwa Roushdy Mohamed

*Lecturer of Internal Medicine & Endocrinology
Faculty of Medicine Ain-Shams University*

Dr. Rana Hashem Ibrahim

*Lecturer of Internal Medicine & Endocrinology
Faculty of Medicine Ain-Shams University*

*Faculty of Medicine
Ain Shams University*

2019

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I was honored to work under the supervision of **Dr. Salwa Seddik Hosny**, Professor of Internal Medicine & Endocrinology, Faculty of Medicine Ain-Shams University, for her vital assistance and unlimited co-operation. She had generously offered me much of her time, precious advice and variable guidance throughout this work.*

*I wish to express my deepest thanks and gratitude to **Dr. Rania Sayed Abd El Baky**, Professor of Internal Medicine & Endocrinology, Faculty of Medicine Ain-Shams University, for her close supervision, generous efforts and constant encouragement. She had scarified a lot of her busy time to teach me and revise over step of this thesis.*

*I would like to express my sincere thanks to **Dr. Yara Mohamed Eid**, Professor of Internal Medicine & Endocrinology, Faculty of Medicine Ain-Shams University, who kindly offered me much of his time, experience, valuable help and effort in the immunohistochemical aspect*

*I would like to express my sincere thanks to **Dr. Magwa Roushdy Mohamed**, Lecturer of Internal Medicine & Endocrinology, Faculty of Medicine Ain-Shams University, who kindly offered me much of his time, experience, valuable help and effort in the immunohistochemical aspect.*

*I would like to express my sincere thanks to **Dr. Rana Hashem Ibrahim**, Lecturer of Internal Medicine & Endocrinology, and Faculty of Medicine Ain-Shams University, who kindly offered me much of his time, experience, valuable help and effort in the immunohistochemical aspect.*

*I wish to express my deepest thanks and gratitude to **radiology department Ain shams university hospital** for providing carotid duplex for patient involved in our study, which provided us with valuable data for our study.*

Mark Nabil Bios

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction	1
Aim of the Work.....	3
<i>Review of Literature</i>	
• Diabetes and Atherosclerosis	4
• Microbiota	27
• Microbiota... Diabetes, obesity and atherosclerosis.....	52
Subject and Methods	68
Results	83
Discussion	100
Summary and Conclusion	109
Recommendation.....	111
References	112
Arabic Summary.....	-

List of Tables

Table No.	Title	Page No.
Table (1):	Showing Diagnostic Criteria for Diabetes Mellitus.....	6
Table (2):	Summarizing different diabetic complications	6
Table (3):	Shows recommendations of statins and combination treatment in adults with Diabetes.....	13
Table (4):	Shows recent Recommendations for cardiovascular risk factor management in patients with diabetes	14
Table (5):	Shows Fontaine's clinical classification for grading of PAD.....	25
Table (6):	Showing summary of treatment of PAD in diabetics	26
Table (7):	Showing classification of bacteria present in human intestine	28
Table (8):	Shows the expected beneficial effects of GUT microbiota in clinical practice	40
Table (9):	Shows microbiota species increased in type 2 diabetes mellitus patients	53
Table (10):	Shows dietary sources rich in <i>TMAO</i> or its metabolites	64
Table (11):	Comparison between group I and group II regarding demographic data and clinical data.	89
Table (12):	Comparison between group I and group II regarding laboratory results.....	90
Table (13):	Comparison between PCR cut-off threshold of the two studied groups.	91
Table (14):	Correlation between PCR cut-off threshold and the other studied parameters in all patients, group I and group II.....	91
Table (15):	Relation between PCR cut-off threshold and the other studied parameters in all patients.	92
Table (16):	Receiver operating characteristic curve (ROC) for PCR cut-off threshold as a predictor for atherosclerosis in type II diabetic patients.	93

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathophysiology of diabetes induced vascular injury.	9
Figure (2):	Shows Age-adjusted cardiovascular disease (CVD) mortality rates among Framingham Heart Study participants with and without DM by sex and period.....	16
Figure (3):	Temporal aspects of microbiota establishment and maintenance and factors influencing microbial composition	30
Figure (4):	Schematic representation of the predominant microbiota composition and density at different regions in the human gastrointestinal tract.....	31
Figure (5):	Phylogenic tree analysis of intestinal microbiota	33
Figure (6):	Hemostatic relationship between human host and intestinal microbiota	39
Figure (7):	Shows an overview of carbohydrates metabolism by anaerobic bacteria in large intestine, boxes show important short chain fatty acids (SCFA).....	41
Figure (8):	The balance between microbiota community determines its contribution to health and disease, the central column represents the functions of the overall community rather than one species	42
Figure (9):	Shows potential protective action of probiotics.....	44
Figure (10):	Shows different effects of dysbiosis.....	44
Figure (11):	Association of intestinal microbiota with diseases outside of the gastrointestinal tract.....	50
Figure (12):	Show important short chain fatty acids metabolism by GUT microbiota.....	55
Figure (13):	Showing relation of altered GUT microbiota and development of atherosclerosis	61
Figure (14):	Shows role of Gut microbiota in pathogenesis of hypertension, atherosclerosis, and arterial thrombosis	65
Figure (15):	Showing Michigan neuropathy screening instrument questionnaire A higher score (out of a maximum of 13 points) indicates more neuropathic symptoms and requires brief neurological assessment.	69

List of Figures (Cont.)

Fig. No.	Title	Page No.
Figure (16):	Showing Insulin ELISA standard curve.	76
Figure (17):	Shows curve for isolation of positive stool samples for <i>L. acidophilus</i> ATCC 4356	79
Figure (18):	Shows significant difference between the 2 groups regarding anti-diabetic medications (P-value: 0.041).....	94
Figure (19):	Shows significant difference between the 2 groups regarding the 2 hrs PP blood sugar (P-value: 0.015).....	94
Figure (20):	Shows significant difference between the 2 groups regarding glycated hemoglobin (HBA _{1c}) (P-value: 0.023).....	95
Figure (21):	Shows significant difference between the 2 groups regarding intimal media thickness (IMT) (P-value< 0.001).....	95
Figure (22):	Shows no significant difference between positive and negative cases for PCR for <i>Lactobacillus acidophilus</i> in two groups (P-value: 0.578)	96
Figure (23):	Shows significant difference between the 2 groups regarding PCR cut off threshold (P-value: 0.016).....	96
Figure (24):	Showing positive Correlation between PCR cut-off threshold and 2 hours post prandial blood sugar (2 hrs PP) in all cases (P-value: 0.031).....	97
Figure (25):	Showing positive Correlation between PCR cut-off threshold and HBA _{1c} in all cases (P-value: 0.026).	97
Figure (26):	Shows positive correlation between PCR cut-off threshold and hours post prandial blood sugar (2 hrs PP) in group (I) (P-value: 0.05).....	98
Figure (27):	Showing positive Correlation between PCR cut-off threshold and HBA _{1c} In-group (I) (P-value: 0.049).	98
Figure (28):	Showing positive correlation between PCR cut-off threshold and intimal media thickness (IMT) in group (I) (P-value: 0.045).	99

List of Abbreviations

Abb.	Full term
2hr PP	Two hours post prandial plasma glucose
ABI.....	ankle-brachial index
ADA	American Diabetes Association
AGEs.....	Advanced glycation end products
AHA	American Heart Association
AHA/ACC.....	American Heart Association and American College of Cardiology
Angptl4	Angiopoietin-like 4
ApoB	Apolipoprotein B
CAD	Coronary artery disease
CDC	Center for Disease Control and Prevention
CVS.....	Cerebrovascular stroke
DM	Diabetes melitis
ESC/EAS.....	European Society of Cardiology and European Atherosclerosis Society.
FFAs	Free fatty acids.
FIAF.....	Fasting-induced adipose factor
FMO3	Flavin-containing monooxygenase form 3
FPG.....	Fasting plasma glucose
GDM	Gestational diabetes mellitus
GLP-1.....	Glucagon-like peptide-1
HBA1C.....	Glycosylated hemoglobin
HDL	High density lipoproteins

List of Abbreviations (Cont.)

Abb.	Full term
IDF.....	International diabetes federation
IL-6.....	Interleukin 6
IMT.....	Intima media thickness
Interferon- α	Interferon gamma
IR	Insulin resistance
LDL.....	Low density lipoproteins
LPL	Lipoprotein lipase
LPS	Lipopolysaccharides
NDR	Swedish National Diabetes registry
NF- κ B.....	Nuclear factor kappa B
NO.....	Nitric oxide
PAD.....	Peripheral arterial disease
PCA.....	Protocatechuic acid
PCR CT.....	Polymerase chain reaction cut-off threshold
PCR.....	Polymerase chain reaction
ROS.....	Reactive oxygen species
SCFA.....	Short chain fatty acids
TLR5	Toll-like receptor 5
TMA	Trimethylamine
TMAO	Trimethylamine-N-oxide
TNF- α	Tumor necrosis factor alpha
VCAM-1	Vascular cell adhesion molecule-1
VLDL	Very low-density lipoproteins

INTRODUCTION

Atherosclerosis is a major burden of modern society and according to the 2018 report by the World Health Organization (WHO), ischemic heart disease, a major complication of atherosclerosis; is the leading cause of death worldwide (*WHO, 2018*).

Diabetes is considered an important risk factor for the development and severity of all forms of atherosclerosis, including peripheral arterial disease (PAD), coronary artery disease (CAD), and cerebrovascular disease (CVD) (*Centers for Disease Control and Prevention, 2014*).

In the past, there have been several studies suggesting that microbes may play a role in the development of atherosclerosis. And recently, colonic bacteria were considered as agents activating chronic inflammatory mechanisms. This is supported by multiple data showing the link between the gut microbiota, inflammation, and autoimmunity (*Stefanie et al., 2018*).

Also, some animal models suggest that obesity, insulin resistance & the metabolic syndrome are associated with alterations of the composition and the functional properties of the gut microbiota (*Chistiakov et al., 2015*).

More recent, a direct connection between microbiota and atherosclerosis has been established through directly atherogenic

compounds like trimethylamine-oxide (TMAO) which is produced by the action of gut microbiota (*Brugere et al., 2014*).

On the other hand, many members of the gut microbiota are now considered to be probiotics; providing many health benefits (*Ewaschuk et al., 2007*).

Bifidobacterium and *Lactobacillus* are two well-known probiotics that are widely used for improving human health. In vitro experiments showed that some of members of those families can assimilate cholesterol and deconjugate bile salts. Resulting in reduction of cholesterol levels and thus being protective against metabolic diseases (*Lebeer et al., 2010*).

Moreover, *Moroti et al.*, reported that the administration of a synbiotic beverage contained *Lactobacillus acidophilus*, *Bifidobacterium bifidum* and *oligofructose*, markedly increased the plasma High Density Lipoproteins (HDL-C) and decreased fasting glycemia in elderly type 2 diabetic patients (*Moroti et al., 2012*).

Other mechanisms also have been postulated for their athero-protective role including: increasing colonic short chain fatty acids decreasing low Density Lipoproteins (LDL) and cholesterol synthesis, lowering inflammatory cytokines ie: interleukin six (IL-6), interleukin eight (IL-8), Tumor Necrosis Factor Alpha (TNF- α) (*Chistiakov et al., 2015*).

AIM OF THE WORK

To study the association of gut Lactobacillus Acidophilus and the presence of atherosclerosis in type 2 diabetic patients.

Chapter 1

DIABETES AND ATHEROSCLEROSIS

Diabetes is a disorder characterized by chronic hyperglycemia resulting either from a lack of insulin production (type one), from insulin resistance (type two) or both. In the last several decades, an alarming increase in the global prevalence of diabetes has been reported. The financial impact of diabetes to the health care system is enormous causing a two to three times higher cost expenditure than the rest of the population. In ten years, the diabetic population will exceed 700 million, this has been attributed to rising obesity epidemic all over the world (*CDC, 2014*).

According to International diabetes federation (IDF), 425 million people have diabetes in the world and more than 39 million people in the middle east and north Africa region; by 2045 this will rise to 67 million. In 2017, the number of diabetics in Egypt was 8,222.6 (*IDF, 2018*).

Types of diabetes:

Diabetes can be classified into the next general types:

1. *Type 1 diabetes* (absolute insulin deficiency, mostly due to autoimmune β -cell destruction).

2. *Type 2 diabetes* (due to insulin resistance and progressive loss of β -cells of pancreas).
3. *Gestational diabetes mellitus (GDM)* (diagnosed in the second or third trimester of pregnancy that was absent prior to gestation).
4. *Specific types* of diabetes secondary to other etiology, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]), diseases of the exocrine pancreas (such as cystic fibrosis and pancreatitis), and drug- or chemical-induced diabetes (such as with glucocorticoid use).

(ADA, 2018)

Type two diabetes phenotypes:

Type 2 diabetes is the most prevalent diabetes form in adults worldwide, and is characterized by adulthood onset, a strong association with obesity, state of insulin resistance and gradual loss of islet β -cells functions. However, phenotypically, type 2 diabetes is more to be found a heterogeneous condition. In 2018, *Ahlqvist et al.*, identified five replicable clusters of patients with significantly distinguishing characteristics and risk of complications. This was done using a set of available data: age, BMI, HbA1c, estimates of β -cell function and insulin resistance, and presence or absence of autoantibodies. The clusters included

severely insulin-deficient diabetes (SIDD), severe autoimmune diabetes (SAID), severe insulin-resistant diabetes (SIRD), mild age-related diabetes (MARD) and mild obesity-related diabetes (MOD) (Ahlqvist et al., 2018).

Table (1): Showing Diagnostic Criteria for Diabetes Mellitus. (ADA, 2018).

<i>American Diabetes Association Diagnostic Criteria for Diabetes Mellitus</i>	
1. Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours.	<i>or</i>
2. Two-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT). The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.	
3. Glycated hemoglobin (A1c) $\geq 6.5\%$ (48 mmol/mol). The test should be performed in a laboratory using a method that is standardized to the Diabetes Control and Complications Trial (DCCT) assay.	
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L).	
*Criteria 1 to 3 require confirmatory testing; criterion 4 does not.	

Table (2): Summarizing different diabetic complications (*Rich et al., 2009*).

Acute complications	Chronic complications	
	Macro-angiopathy	Micro-angiopathy
Diabetic ketoacidosis	Coronary a. disease	Cardiomyopathy
hyperosmolar Hyperglycemia	Myonecrosis	Nephropathy
Hypoglycemic coma	Peripheral vas. dis.	Retinopathy
Diabetic coma	Stroke	Polyneuropathy
Respiratory infections		
Periodontal disease		

The chronic health complications of diabetes are mainly vascular. Diabetes is believed to shorten the lifespan of a 50-year-old person by approximately 6 years, more than half of which is caused by vascular disease. Vascular complications are usually divided into: microvascular and macrovascular complications. Where elevated blood sugar is found to be a driving force in both large and small vessel disease (*Rao et al., 2011*).

Microvascular complications include: retinopathy and nephropathy. Diabetics have a 20-fold increased relative risk of blindness and a 25-fold higher relative risk of end-stage renal disease (ESRD).

While macrovascular disease is due to atherosclerosis. Diabetes is an important risk factor for the development and severity of all forms of atherosclerosis, including peripheral artery disease (PAD), coronary artery disease (CAD), and cerebrovascular disease (CVD) (*Orasanu et al., 2009*).

Epidemiological studies show that atherosclerosis causes most of the morbidity and mortality in patients with diabetes (*Rao et al., 2011*).

Cardiovascular disease accounts for about 44% of all-cause mortality in the diabetic patients' population, diabetes accounts for 60% of nontraumatic lower-limb amputations and diabetes